Aligos Therapeutics Sets Stage for EASL Congress 2025 with Eight Accepted s
SOUTH SAN FRANCISCO, Calif. April 23, 2025 Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical-stage biopharmaceutical company dedicated to enhancing patient outcomes through advanced therapies targeting liver and viral diseases, today announced that eight of its research abstracts have been accepted for poster presentations at the European Association for the Study of the Liver (EASL) Congress 2025. The event is scheduled to take place from May 7 to May 10, 2025, in Amsterdam, Netherlands.
The accepted abstracts highlight Aligos’s commitment to addressing pressing challenges in liver and viral disease management. Specific details regarding the content of the abstracts have yet to be disclosed, but they are expected to showcase the company’s innovative research and potential therapeutic developments.
In conjunction with this announcement, it s worth noting that Aligos Therapeutics Inc. has experienced a decline in share performance relative to the broader market over the past month. Recent data indicates that Aligos’s shares have underperformed compared to the CSIMarkets index, which tracks the performance of competitors and alternatives within the biopharmaceutical sector. This trend raises questions about market perceptions of the company s recent advancements and ongoing projects.
The EASL Congress presents a significant opportunity for Aligos Therapeutics to engage with leading experts in hepatology and share insights on their latest findings. The acceptance of eight abstracts underscores the company’s active role in contributing to the evolving landscape of liver disease research and treatment.
For additional details on the abstracts, attendees and interested parties can visit the EASL website.
Overall, the upcoming EASL Congress promises to be a pivotal event for Aligos Therapeutics as it aims to foster collaborations and showcase its commitment to developing effective therapies for liver and viral diseases amidst a year of shareholder challenges.
Comments